PHusis Therapeutics Management Team

D. Lynn Kirkpatrick, PHD
President and CEO
Former Co-founder of ProlX Pharmaceuticals and Professor of Chemistry and Biochemistry at the University of Regina, Canada, Lynn Kirkpatrick has spent over 30 years in cancer drug discovery and development. From 1999 to 2006 Dr. Kirkpatrick was CEO of ProlX Pharmaceuticals, taking three small molecules from bench to bedside. When ProlX was acquired by Biomira Inc., a publicly traded company, she became the Chief Scientific Officer of the merged company which changed its name to Oncothyreon, Inc. in 2007. Following her resignation from Oncothyreon in 2009, Dr. Kirkpatrick co-founded PHusis Therapeutics with Drs. Powis, Meuillet and Zhang. Dr. Kirkpatrick received her PhD from the University of Saskatchewan and did post-doctoral research at Yale University School of Medicine. She has published extensively in the area of targeted cancer drug discovery and development with over 120 papers and presentaions and holds numerous patents for novel cancer drugs.

NAZANIN BERENJIAN,
DIRECTOR OF FINANCE
Ms. Berenjian has over twenty years of experience as controller and financial analyst in small companies in Southern California. She has been involved with companies in all stages of development, and has managed all aspects of accounting for a compliance banking company. She has co-ordinated diligence activities for companies undergoing acquisition, supervising audits and overseeing the transition of accounting policies into new company.

GARTH POWIS, DPHIL
SCIENTIFIC CO-FOUNDER, Director, Chair of SAB
Dr. Powis is the Director of the NCI Designated Research Cancer Center at the Sanford Burnham Medical Research Institute (SBMRI) in San Diego California. Former Chair of Experimental Therapeutics and Director of the Center for Targeted Therapy at The University of Texas M. D. Anderson Cancer Center, Dr. Powis is a leader in the field of signal transduction and has extensive experience in the development of anticancer drugs that act against cell signaling pathways including those involving PH domain regulated proteins. Dr. Powis has over 350 publications, and books, 12 patents and has been involved in the development of three anti-cancer agents that are now in clinical development.

EMMANUELLE MEUILLET, PHD
SCIENTIFIC CO-FOUNDER
Dr. Meuillet, Associate Research Professor, Departments of Nutritional Sciences and Molecular and Cellular Biology, at the University of Arizona Comprehensive Cancer Center, received her Ph.D. in Biochemistry and Pharmacology from the University Louis Pasteur, France. She completed post-doctoral training at the Children’s Memorial Hospital at Northwestern University, Chicago and at the Arizona Comprehensive Cancer Center, Tucson. She has coauthored over 50 papers in the field of cellular signaling and lipidology and studies the process of inflammation, a driving force of cancer metastasis.

SHUXING ZHANG, PHD
SCIENTIFIC CO-FOUNDER
Dr. Shuxing Zhang, Assistant Professor, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, obtained his Ph.D. in computational and medicinal chemistry from the University of North Carolina at Chapel Hill. With more than ten years industrial and academic experience in computational drug discovery and development, Dr. Zhang has broad experience in medicinal chemistry, biophysics and computational biology. He has been involved in cancer therapeutics design against numerous protein targets using cutting-edge cheminformatics, bioinformatics and systems biology integrated platforms for molecular interaction pathway analysis, lead identification/optimization, and ADMET studies. His research has earned him the American Chemical Society 2008 Hewlett-Packard Outstanding Scholar Award.

Board Members

D. LYNN KIRKPATRICK, PHD, CHAIR

PATRICK TROWN, D. PHIL, DIRECTOR
Biotechnology Consultant. Dr. Trown, a seasoned biopharmaceutical executive, held senior positions in preclinical and product development at Lederle Laboratories, Hoffmann-La Roche, Xoma, and Onyx Pharmaceuticals. Dr. Trown focus is small emerging companies and he has a wealth of experience in positioning of new agents for clinical use.

STEPHEN A. HURLY, MBA, DIRECTOR
CEO of Viventia Bio Inc.
Former CEO Merchant & Investment Banking, Burrill & Company, Mr. Hurly served investment banking needs of businesses in the healthcare, biotechnology and pharmaceutical sectors. Steve has more than 15 years experience having served as: Managing Director, Investment Banking, Boenning & Scattergood, Inc. Managing Director/Head of the Health Care Group at Janney Montgomery Scott, LLC.Hambrecht & Quist and JP Morgan in San Francisco.

DAVID J. CHAPLIN, PHD, DIRECTOR
Dr. Chaplin is former Chief Scientific Officer of OXiGENE where he guided lead agent ZYBRESTAT from discovery to Phase III trials and OXi4503 into Phase I. At OXiGENE he developed productive international drug discovery and research collaborations with numerous academic institutions in the USA, Canada and Europe and was closely involved in five financings raising over 200 million dollars. Prior to that Dr. Chaplin oversaw integration of worldwide oncology research operations following merger of RPR and HMR to form AVENTIS and was responsible for their Global Oncology research operations covering discovery through end of Phase I. Additionally he co-founded Angiogene Pharmaceuticals and licensed its lead agent to AstraZeneca.

ROBERT A. KRAMER, PHD, DIRECTOR
Dr. Kramer is former Vice President and Head of Discovery for Oncology Therapeutics at Janssen Research & Development, LLC. He was responsible for leading Global Discovery, focusing on aberrant signaling cascades in tumor cells, as well as epigenetic reprogramming and tumor immunology using both small molecule and protein-based large molecule approaches. Dr. Kramer joined Janssen Research & Development from Bristol-Myers Squibb (BMS), where he was VP Drug Discovery and Research site head in Princeton, NJ where he provided scientific leadership and strategic oversight for many preclinical Oncology and Immunology programs/projects that entered development, several of which have gone on to receive regulatory approvals for treating patients with chronic myeloid leukemia, breast cancer and melanoma.